Seoul: A South Korean firm has started production of the COVID-19 rapid antibody testing kits in its Indian subsidiary plant in Haryana’s Manesar, to meet the growing demand of the medical equipment in India and other parts of the world, a press release issued by the Indian embassy here said on Tuesday. Also Read - India's New FDI Norms 'Discriminatory', Against General Trend of Free Trade: China

SD Biosensor Healthcare Pvt Ltd is producing the test kits with a capacity of 500,000 tests per week and the first batch was rolled out on April 19, it said. Also Read - COVID-19: Trump Says China 'Could Face Consequences' if 'Knowingly Responsible' For Virus



“This is an excellent example of India”s ”Make in India for the World” as the company plans to ramp up production to meet growing demand in India as well as other parts of the world,” the press release said. Also Read - Community Transmission of COVID-19 in Clusters? Random Sampling Results by ICMR Reveal Indications

The strategy and corporate structure of this company exemplifies the strong partnership between the two countries specially in the field of medical technology.



Indian Ambassador to South Korea Sripriya Ranganathan on Tuesday also visited the company’s manufacturing facility accompanied by its CEO Lee Hyo-Keun.

“SD Biosensor has just started production from its Manesar facility with a capacity of 500,000 rapid test kits per week. This will be further enhanced in coming weeks to meet growing demand,” the embassy tweeted.

This comes at a time when China-made rapid testing kits have been found to be faulty. In the light of it, the Indian Council Of Medical Research (ICMR) on Tuesday urged all states to wait for two days before trialing the rapid test kits as the government was investigating into faulty kits.

(With agency inputs)